Can a patient safely take atomoxetine (Strattera) 40 mg, bupropion (Wellbutrin) 300 mg, and trazodone together?

Can This Medication Combination Be Used Safely?

Yes, a patient can generally take atomoxetine (Strattera) 40 mg, bupropion (Wellbutrin) 300 mg, and trazodone together, but this combination requires careful monitoring due to a significant pharmacokinetic interaction between atomoxetine and bupropion that increases atomoxetine exposure approximately 5-fold. 1

Critical Drug Interaction: Bupropion and Atomoxetine

Bupropion significantly inhibits CYP2D6, the primary enzyme metabolizing atomoxetine, leading to a 5.1-fold increase in atomoxetine systemic exposure (AUC). 1 This interaction occurs because:

• Bupropion acts as a potent CYP2D6 inhibitor, converting extensive metabolizers into functional poor metabolizers 1
• Atomoxetine's maximum concentration (Cmax) increases from 226 ng/mL to 386 ng/mL when combined with bupropion 1
• The half-life of atomoxetine is prolonged with bupropion co-administration 1

Dosing Adjustment Required

When atomoxetine is used with potent CYP2D6 inhibitors like bupropion, the FDA label recommends initiating atomoxetine at a reduced dose and only increasing to the usual target dose if symptoms fail to improve after 4 weeks and the initial dose is well-tolerated. 2 Specifically:

• Start atomoxetine at 40 mg/day (which is already the patient's current dose) 2
• Do not exceed 80 mg/day total when combined with bupropion 2
• Monitor closely for increased atomoxetine-related adverse effects 2

Safety Considerations for the Triple Combination

Cardiovascular Monitoring

Both atomoxetine and bupropion can affect cardiovascular parameters, requiring baseline and ongoing monitoring: 3

• Obtain personal and family cardiac history before initiating treatment 3
• Monitor heart rate and blood pressure regularly, as atomoxetine may increase both 3
• Bupropion should be avoided in patients with uncontrolled hypertension 3
• Consider ECG if cardiac risk factors are present 3

Seizure Risk

Bupropion lowers the seizure threshold and should be used cautiously in patients with seizure disorders or factors that increase seizure risk. 3 The risk is dose-dependent, and the 300 mg dose mentioned is at the upper end of recommended dosing 3

Psychiatric Monitoring

All three medications require monitoring for psychiatric adverse effects: 2

• Atomoxetine carries an FDA black box warning for suicidal ideation in children and adolescents, with close monitoring recommended especially in the first months of treatment 2
• Bupropion is contraindicated in patients with seizure disorders and should be used cautiously in those with bipolar disorder 3
• Monitor for behavioral activation, agitation, or emergence of manic symptoms 3

Trazodone's Role in This Combination

Trazodone is commonly prescribed alongside activating antidepressants like bupropion and SSRIs to manage insomnia, with clinical experience supporting this practice. 4 The evidence shows:

• Trazodone is prescribed significantly more often with bupropion (23% of patients) compared to tricyclic antidepressants (13%) 4
• Clinical experience suggests general safety and efficacy when combining trazodone with other antidepressant classes 3
• Recent research demonstrates that atomoxetine combined with trazodone (50 mg atomoxetine + 80 mg trazodone) significantly improved obstructive sleep apnea parameters without major safety concerns 5

Trazodone Dosing Considerations

When using trazodone for insomnia in combination with other medications, lower doses than those used for depression are typically employed: 3

• Typical insomnia dosing ranges from 25-100 mg at bedtime 3
• These medications are not FDA-approved for insomnia, and efficacy is not well-established for this indication 3
• Monitor for daytime sedation, especially when combined with other CNS-active medications 3

Serotonin Syndrome Risk

While the risk is relatively low with this specific combination, caution is warranted when combining multiple serotonergic agents: 3

• Trazodone has serotonergic properties 3
• Bupropion has minimal serotonergic activity, reducing this concern 3
• Atomoxetine primarily affects norepinephrine, not serotonin 2
• Monitor for mental status changes, neuromuscular hyperactivity, and autonomic instability, particularly in the first 24-48 hours after starting or dose adjustments 3

Clinical Monitoring Plan

Implement the following monitoring schedule:

• Initial phase: Weekly visits for the first month to assess tolerability and adverse effects 3
• Stabilization phase: Monthly visits for 3 months to monitor efficacy and side effects 3
• Maintenance phase: Every 3-4 months once stable response achieved 3
• At each visit: Assess blood pressure, heart rate, weight, psychiatric symptoms, and treatment response 3

Common Pitfalls to Avoid

Key errors to prevent:

• Do not use standard atomoxetine dosing when combined with bupropion without considering the CYP2D6 interaction 1
• Do not abruptly discontinue any of these medications, particularly if trazodone is being used (though less critical than with benzodiazepines) 3
• Do not ignore cardiovascular monitoring, especially given the combination of two medications that can affect blood pressure and heart rate 3
• Do not prescribe bupropion late in the day as the second dose should be given before 3 PM to minimize insomnia risk 3
• Do not combine with MAOIs - atomoxetine is contraindicated with MAOIs and requires a 2-week washout period 2

Bottom Line

This triple combination can be used safely with appropriate dose adjustment of atomoxetine (keeping it at or below 40-80 mg/day given the bupropion interaction), cardiovascular monitoring, and psychiatric surveillance. 2, 1 The combination addresses multiple therapeutic targets: atomoxetine for ADHD, bupropion for ADHD/depression/smoking cessation, and trazodone for sleep, with established clinical experience supporting such polypharmacy when medically indicated 3, 4